One of the most studied therapeutic interventions is anti-angiogenic therapy, such as Bevacizumab, which targets the formation of blood vessels within the tumor, thereby restricting the tumor’s nutrient supply and inhibiting its growth by blocking VEGF, a chemokine responsible for angiogenesis. This evidence concerns the gene VEGFA and neoplasm.